** Shares of drug developer Relmada Therapeutics fall 77.6% to 62 cents premarket
** Co says its depression treatment is "unlikely" to meet the main goal of a late-stage trial, according to an independent data monitoring committee's analysis
** Co was testing the treatment, REL-1017, as an additional treatment for major depressive disorder to be used in combination with other approved anti-depressants
** Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program - RLMD
** Co had about $54.1 million in cash and cash equivalents as of September 30, 2024
** Up to last close, stock down 33% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.